Deborah Dunsire has been a director of Alexion since January 2018. Dr. Dunsire has more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc. Dr. Dunsire currently serves as President and Chief Executive Officer of Lundbeck, a global pharmaceutical company specializing in brain diseases.
Dr. Dunsire currently serves on the board of Ultragenyx Pharmaceutical, Inc., a publicly traded biotechnology company. She previously served on the boards of XTuit Pharmaceuticals, Inc., Takeda Pharmaceuticals, Allergan, Inc., and FORUM Pharmaceuticals, Inc.
Dr. Dunsire is a member of the Leadership and Compensation Committee and the Science and Innovation Committee.